Streetbeat News

PVCT

Provectus Biopharmaceuticals Inc

http://www.provectusbio.com/

Employees

Industry

Pharmaceutical Preparation Manufacturing

Open

0.12

Mkt cap

48M

Volume

57K

High

0.12

P/E Ratio

-11.43

52-wk high

0.23

Low

0.11

Div yield

N/A

52-wk low

0.04

Provectus Biopharmaceuticals has announced a $3 million seed financing round for its spinoff company, VisiRose, which is focused on developing eye drugs based on Rose Bengal.

Portfolio Pulse from

January 14, 2025 | 1:15 pm

Provectus Biopharmaceuticals, Inc. (PVCT) held its Q4 2024 earnings call, discussing the company's financial performance and updates. Key participants included Alyssa Barry, Ed Pershing, and Dominic Rodrigues.

Portfolio Pulse from

November 14, 2024 | 10:30 pm

Provectus Biopharmaceuticals presented non-clinical data on their rose bengal sodium (RBS) for treating full-thickness cutaneous wounds at the SID 2024 Annual Meeting. The data shows that RBS accelerates wound closure and improves healing.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 12:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.